The trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.

AVVIGO is an intravascular ultrasound (IVUS) and fractional flow reserve (FFR) system designed to provide high-quality IVUS ...

Boston Scientific (NYSE: BSX) today announced the completion of its $3.7 billion acquisition of Axonics, Inc. (Nasdaq: AXNX).

The medical device maker has completed more than 40 acquisitions in recent years, helping turn it into one of the state’s ...

In a report released today, Richard Newitter from Truist Financial assigned a Buy rating to Boston Scientific (BSX – Research Report). The ...

Boston Scientific (BSX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Travis Steed ...

Boston Scientific Corp. last week announced that it has closed on its acquisition of Irvine-based medical device maker ...

Spread the loveBoston Scientific, headquartered in Marlborough, has seen its stock surge by 50%, driven by a series of ...

For valuable insights into Boston Scientific's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our ...

Boston Scientific Corporation BSX recently closed the acquisition of Axonics, Inc., a medical technology company focused on the development and commercialization of differentiated devices to treat ...

for stroke risk reduction in patients with non-valvular atrial fibrillation following a cardiac ablation were presented at ...

Boston Scientific temporarily paused enrolment in its AVANT GUARD trial in October to “assess a few unanticipated ...